We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sarepta to Report Q2 Earnings: What's in Store for the Stock?
Read MoreHide Full Article
Key Takeaways
{\"0\":\"SRPT expects Q2 sales of $530M and EPS of $1.11, both up significantly from the prior year.\",\"1\":\"Elevidys sales hit $282M in Q2, though safety issues led to a temporary market withdrawal.\",\"2\":\"SRPT plans $400M in annual savings via layoffs, pipeline reprioritization and restructuring.\"}
We expect Sarepta Therapeutics (SRPT - Free Report) to report second-quarter 2025 earnings on Aug. 6, after market close. The company’s earnings missed estimates by a wider margin in the last reported quarter.
The Zacks Consensus Estimate for total sales and earnings per share (EPS) is pegged at approximately $530 million and $1.11, respectively. Both metrics indicate a significant increase from the year-ago period.
Factors Likely to Shape SRPT’s Upcoming Results
Sarepta currently has four marketed products in its portfolio, all targeting Duchenne muscular dystrophy (DMD). These include the one-shot gene therapy Elevidys and three PMO therapies (Exondys 51, Vyondys 53 and Amondys 45).
Last month, the company issued preliminary numbers for total net product revenues during the second quarter, which stand at $513 million. This includes $282 million from Elevidys sales. Sarepta also reported preliminary combined adjusted R&D and SG&A expenses of around $294 million for the quarter.
The stock has been facing a lot of heat from investors after three patient deaths were linked to its gene therapy treatments and attributed to acute liver failure (ALF). While two deaths occurred in patients after receiving Elevidys, one was caused by an experimental limb-girdle muscular dystrophy (LGMD) therapy. All deaths occurred in non-ambulatory patients and were linked to the AAVrh74 gene therapy vector, used in both Elevidys and Sarepta’s experimental LGMD therapies.
However, the FDA cleared Elevidys for use in ambulatory patients last week after finding no link between the therapy and the Brazilian patient’s death. While Sarepta intends to resume delivery of Elevidys shipments soon, we also expect it to provide an update on the sales guidance for the product. Sarepta previously announced it would not host a conference call for Q2 earnings.
To address the safety issue in non-ambulatory patients, Sarepta is working to create a new protocol with an enhanced immunosuppression regimen to make Elevidys administration safer for non-ambulatory DMD patients. The company plans to submit these findings to the FDA in hopes of resuming dosing in the non-ambulatory patient population.
Last month, Sarepta initiated a restructuring plan to save nearly $400 million annually starting in 2026. To achieve this target, the company has decided to lay off 36% of its workforce — around 500 employees — which is expected to save nearly $120 million per year.
Sarepta plans to generate around $300 million in annual savings by reprioritizing its pipeline. As part of this plan, it paused development of its LGMD pipeline and instead shifted focus to the siRNA programs, which were acquired as part of a multi-billion-dollar licensing deal with Arrowhead Pharmaceuticals . Per this deal, Sarepta acquired exclusive rights to Arrowhead’s four clinical-stage programs, each being evaluated in separate phase I/II studies. These include SRP-1001 in facioscapulohumeral muscular dystrophy (FSHD), SRP-1002 in idiopathic pulmonary fibrosis (IPF), SRP-1003 in myotonic dystrophy type 1 (DM1) and SRP-1004 in spinocerebellar ataxia 2 (SCA2). Initial data on the FSHD and DM1 programs are expected before year-end.
SRPT’s Earnings Surprise History
The biotech firm’s performance has been mixed over the past four quarters. Its earnings missed estimates in two of the trailing four quarters, beat the mark once and met the same on another occasion, resulting in a negative average surprise of 194.53%.
The stock has underperformed the industry this year so far, as shown in the chart below.
Image Source: Zacks Investment Research
What Our Model Predicts for SRPT
Per our proven model, companies with the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) have a good chance of delivering an earnings beat. This is not the case here. You can uncover the best stocks before they’re reported with our Earnings ESP Filter.
Sarepta has an Earnings ESP of 0.00% and a Zacks Rank #4 (Sell) at present.
Here are some biotech stocks that have the right combination of elements to beat on earnings this time around:
Genmab (GMAB - Free Report) has an Earnings ESP of +10.03% and a Zacks Rank of 2 at present.
Shares of GMAB have gained 4% year to date. It beat on earnings in two of the trailing four quarters and missed in the other two, delivering an average surprise of 14.90%. Genmab intends to report second-quarter results on Aug. 7.
Acadia Pharmaceuticals (ACAD - Free Report) currently has an Earnings ESP of +17.43% and a Zacks Rank of 3.
ACAD stock has surged 28% this year so far. It beat on earnings in three of the last four quarters and missed in the other one, delivering an average surprise of 19.58%. Acadia will report second-quarter earnings on Aug. 6.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Sarepta to Report Q2 Earnings: What's in Store for the Stock?
Key Takeaways
We expect Sarepta Therapeutics (SRPT - Free Report) to report second-quarter 2025 earnings on Aug. 6, after market close. The company’s earnings missed estimates by a wider margin in the last reported quarter.
The Zacks Consensus Estimate for total sales and earnings per share (EPS) is pegged at approximately $530 million and $1.11, respectively. Both metrics indicate a significant increase from the year-ago period.
Factors Likely to Shape SRPT’s Upcoming Results
Sarepta currently has four marketed products in its portfolio, all targeting Duchenne muscular dystrophy (DMD). These include the one-shot gene therapy Elevidys and three PMO therapies (Exondys 51, Vyondys 53 and Amondys 45).
Last month, the company issued preliminary numbers for total net product revenues during the second quarter, which stand at $513 million. This includes $282 million from Elevidys sales. Sarepta also reported preliminary combined adjusted R&D and SG&A expenses of around $294 million for the quarter.
The stock has been facing a lot of heat from investors after three patient deaths were linked to its gene therapy treatments and attributed to acute liver failure (ALF). While two deaths occurred in patients after receiving Elevidys, one was caused by an experimental limb-girdle muscular dystrophy (LGMD) therapy. All deaths occurred in non-ambulatory patients and were linked to the AAVrh74 gene therapy vector, used in both Elevidys and Sarepta’s experimental LGMD therapies.
While the two Elevidys deaths had initially prompted Sarepta to suspend Elevidys dosing for non-ambulatory patients, the death of an ambulatory DMD patient in Brazil post-treatment with the therapy led to the product being withdrawn completely from the market.
However, the FDA cleared Elevidys for use in ambulatory patients last week after finding no link between the therapy and the Brazilian patient’s death. While Sarepta intends to resume delivery of Elevidys shipments soon, we also expect it to provide an update on the sales guidance for the product. Sarepta previously announced it would not host a conference call for Q2 earnings.
To address the safety issue in non-ambulatory patients, Sarepta is working to create a new protocol with an enhanced immunosuppression regimen to make Elevidys administration safer for non-ambulatory DMD patients. The company plans to submit these findings to the FDA in hopes of resuming dosing in the non-ambulatory patient population.
Last month, Sarepta initiated a restructuring plan to save nearly $400 million annually starting in 2026. To achieve this target, the company has decided to lay off 36% of its workforce — around 500 employees — which is expected to save nearly $120 million per year.
Sarepta plans to generate around $300 million in annual savings by reprioritizing its pipeline. As part of this plan, it paused development of its LGMD pipeline and instead shifted focus to the siRNA programs, which were acquired as part of a multi-billion-dollar licensing deal with Arrowhead Pharmaceuticals . Per this deal, Sarepta acquired exclusive rights to Arrowhead’s four clinical-stage programs, each being evaluated in separate phase I/II studies. These include SRP-1001 in facioscapulohumeral muscular dystrophy (FSHD), SRP-1002 in idiopathic pulmonary fibrosis (IPF), SRP-1003 in myotonic dystrophy type 1 (DM1) and SRP-1004 in spinocerebellar ataxia 2 (SCA2). Initial data on the FSHD and DM1 programs are expected before year-end.
SRPT’s Earnings Surprise History
The biotech firm’s performance has been mixed over the past four quarters. Its earnings missed estimates in two of the trailing four quarters, beat the mark once and met the same on another occasion, resulting in a negative average surprise of 194.53%.
Sarepta Therapeutics, Inc. Price and EPS Surprise
Sarepta Therapeutics, Inc. price-eps-surprise | Sarepta Therapeutics, Inc. Quote
The stock has underperformed the industry this year so far, as shown in the chart below.
Image Source: Zacks Investment Research
What Our Model Predicts for SRPT
Per our proven model, companies with the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) have a good chance of delivering an earnings beat. This is not the case here. You can uncover the best stocks before they’re reported with our Earnings ESP Filter.
Sarepta has an Earnings ESP of 0.00% and a Zacks Rank #4 (Sell) at present.
You can see the complete list of today’s Zacks #1 Rank stocks here.
Stocks With the Favorable Combination
Here are some biotech stocks that have the right combination of elements to beat on earnings this time around:
Genmab (GMAB - Free Report) has an Earnings ESP of +10.03% and a Zacks Rank of 2 at present.
Shares of GMAB have gained 4% year to date. It beat on earnings in two of the trailing four quarters and missed in the other two, delivering an average surprise of 14.90%. Genmab intends to report second-quarter results on Aug. 7.
Acadia Pharmaceuticals (ACAD - Free Report) currently has an Earnings ESP of +17.43% and a Zacks Rank of 3.
ACAD stock has surged 28% this year so far. It beat on earnings in three of the last four quarters and missed in the other one, delivering an average surprise of 19.58%. Acadia will report second-quarter earnings on Aug. 6.